Staff Reports
The Fifth Circuit in New Orleans heard heated oral argument this week in Louisiana’s bid to pause the FDA rule that lets mifepristone be dispensed by mail and through telehealth. At the center: a request for a narrow but powerful administrative stay under 5 U.S.C. §705 that would roll back the in‑person pickup rule and reshape access to abortion pills nationwide while the agency finishes a safety review it admits is incomplete.
What happened this week
The legal move Louisiana wants
Louisiana’s solicitor general, Ben Aguiñaga, asked the court to issue a §705 stay that would suspend the 2023 FDA REMS change allowing certified pharmacies and mail‑order dispensing of mifepristone. Attorney General Liz Murrill put her state’s weight behind the move, saying Louisiana has been harmed by pills arriving in the state and by Medicaid costs tied to complications. The Justice Department, defending the FDA, told judges it prefers the agency finish its safety review rather than have courts rearrange policy on the fly.
Judges pushed back — and rightly so
The three‑judge panel, including Judge Stephen Higginson and Judge Priscilla Richman, pressed both sides hard. Judges asked whether shield laws and out‑of‑state prescribers — not the FDA — are the real drivers of pills entering Louisiana. They grilled the government lawyer, Daniel Winik, for not defending the REMS on its merits and for telling the court to wait for a report. The courtroom exchange exposed a basic problem: if the agency won’t stand behind its own work, who will?
High stakes: access, safety, and the courts
This fight is not theoretical. A Fifth Circuit stay would affect telehealth and mail distribution of mifepristone in every state. Providers warn access would change sharply if mail order is curtailed; some say they could shift to misoprostol‑only regimens, which are different and less common. And any Fifth Circuit move would almost certainly race back to the Supreme Court — so the practical outcome depends as much on procedure and timing as on medicine.
Politics, common sense, and what to watch next
Call it what it is: a legal tug‑of‑war wrapped in politics. Critics allege the White House would rather let the agency delay a report until after Election Day than face the fallout of a candid safety review. Meanwhile, the FDA’s incomplete review and the agency’s unwillingness to defend the 2023 change on the merits hand the Fifth Circuit ammunition to act. Expect a written ruling soon, emergency Supreme Court petitions if the decision goes against either side, and more courtroom theater as the next act.
